Aktis Oncology vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 53)
Aktis Oncology logo

Aktis Oncology

ChallengerHealthcare & Life Sciences

Radiopharmaceuticals

Clinical-stage oncology company completed $318M IPO in Jan 2026 — first biotech IPO of 2026 (Nasdaq: AKTS); Eli Lilly took $100M stake; developing alpha-emitting radiopharmaceutical AKY-1189 targeting Nectin-4 for bladder and other solid tumors.

AI VisibilityBeta
Overall Score
C53
Category Rank
#252 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
52
Perplexity
57
Gemini
53

About

Aktis Oncology is a Boston-based clinical-stage oncology company developing alpha-emitting radiopharmaceuticals against prevalent solid tumors. The company completed a $318 million IPO in January 2026 — the first significant biotech IPO of 2026 — pricing 17.65 million shares at $18 each on the Nasdaq under ticker AKTS. Eli Lilly stepped in to purchase $100 million of the offering.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
up
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

53
Overall Score
90
#252
Category Rank
#2
78
AI Consensus
83
stable
Trend
up
52
ChatGPT
92
57
Perplexity
93
53
Gemini
89
47
Claude
96
54
Grok
95

Key Details

Category
Radiopharmaceuticals
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Aktis Oncology
Radiopharmaceuticals

Integrations

Both integrate with
Moderna is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.